CClinicalTrials.gg
CompletedNCT05662423CARESUpdated Jul 30, 2026

Preventing Childbirth-Related PTSD With Expressive Writing

An interventional study of Expressive Writing about Childbirth and Neutral Writing in PTSD (Childbirth-Related), sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to test a brief psychological intervention given to individuals in the first days following childbirth who have experienced a potentially stressful childbirth. The treatment is aimed at preventing post-traumatic stress disorder following childbirth and promoting maternal-infant bonding.

In the days following childbirth, participants will be asked to write about their childbirth experience or a neutral event for three consecutive days, for around 15 minutes each day. Additionally, they will complete a short survey before and after the intervention about their birth experience and mental health. Around 2 months postpartum (with the option of up to around Month 3 PP), participants will take part in mental health and physiological assessments, and in a brief play session with their infant.

Read the detailed description

Childbirth-related PTSD (CB-PTSD) is a debilitating maternal mental disorder that undermines the well-being of mothers and can interfere with bonding with their infants during an important time of infant development. A significant portion of delivering women, particularly those who have experienced complicated deliveries, are at-risk for developing CB-PTSD. Underrepresented minorities are also at higher risk for CB-PTSD. An estimated 240,000 American women are likely to be affected by CB-PTSD each year.

Currently, there is no recommended intervention for individuals exposed to traumatic childbirth in hospitals in the United States. Immediate postpartum interventions delivered to at-risk women that are low-cost, low-burden, and feasible are lacking. This study will attempt to fill this gap in effective treatment. Evidence shows that expressive writing (EW), or briefly disclosing in writing mainly thoughts and feelings about a highly stressful event, can have positive effects on mental and physical health. Therefore, the investigators will test the therapeutic effects of EW about recent childbirth in women at-risk for CB-PTSD.

02

Conditions studied

  • PTSD (Childbirth-Related)

Keywords

  • Mother-Infant Bonding
  • Postpartum Depression
  • Postpartum PTSD
  • Expressive Writing
03

In context

Stress Disorders, Post-Traumatic

2,239 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 554 are open to participants now.

This study's enrollment of 66 is close to the median of 70 across 1,858 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,537 studies on the registry; 447 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Women who recently delivered at Massachusetts General Hospital (MGH).
  • Women who are at risk for developing CB-PTSD based on their scoring of >16 on the Peritraumatic Distress Inventory (PDI).

Exclusion criteria

Exclusion Criteria:

  • Age \<18 or >50.
  • Stillbirth.
  • Down's Syndrome, other serious genetic disorder in the newborn, or serious birth defect (e.g., microcephaly, spina bifida).
  • Admission to the neonatal intensive care unit (NICU) for more than 1 week or infant that is not medically healthy.
  • Current diagnosable DSM-5 psychotic or bipolar disorder, or current substance abuse disorder.
  • Active suicidality (assessed case by case).
  • Present substance abuse as indicated in medical records.
  • Severe maternal morbidity (assessed case by case).
  • General anesthesia.
  • Inability to understand the study procedures, risks, and side effects, or to otherwise give informed consent for participation due to neurological or other reasons.
  • Inability to understand English.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Expressive Writing about Childbirth

    Subgroup of participants will write about their recent childbirth.

    Behavioral: Expressive Writing about Childbirth

  • Placebo comparator
    Neutral Writing

    Subgroup of participants will write about neutral daily events.

    Behavioral: Neutral Writing

Interventions

  • BehavioralExpressive Writing about Childbirth

    Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.

  • BehavioralNeutral Writing

    Participants will write repeatedly about neutral daily events/tasks not related to childbirth.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the PTSD Checklist for DSM-5 (PCL-5) total score

    The PCL-5 is the standard self-report measure to assess PTSD symptom severity. It lists the 20 DSM-5 symptoms regarding a specified event (scale: 0-80, higher scores means worse outcome). In this study the event is specified to recent personal childbirth.

    Time frame: Pre-Intervention and Post-Intervention (within 1 day of treatment)

  2. Change from baseline in the PTSD Checklist for DSM-5 (PCL-5) total score

    The PCL-5 is the standard self-report measure to assess PTSD symptom severity. It lists the 20 DSM-5 symptoms regarding a specified event (scale: 0-80, higher scores means worse outcome). In this study the event is specified to recent personal childbirth.

    Time frame: Pre-Intervention and Month 2 postpartum (up to around Month 3 PP)

  3. Physiological reactivity as determined from psychophysiologic responses during script-driven traumatic memory recollection of recent childbirth

    The posterior probability score will be determined for each participant from a composite of psychophysiological responses during script-driven imagery of recent traumatic childbirth (in comparison to baseline) that includes assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator frontalis facial muscle electromyogram (EMG) responses in microVolts. The responses to each childbirth script will then be compared with a large database of trauma-exposed subjects by means of a discriminant function analysis, which will yield a posterior probability (PrP) score (higher scores means worse outcome). The PrP scores of the two childbirth scripts will be averaged and will serve as a composite measure of physiological responsivity in the analysis.

    Time frame: Month 2 postpartum (up to around Month 3 PP)

  4. Clinician-Administered PTSD-5 Scale for DSM 5 (CAPS-5)

    The CAPS-5 is the gold-standard interview to diagnose PTSD. It yields a categorical measure of diagnosis and a severity score (scale: 0-80, higher scores means worse outcomes).

    Time frame: Month 2 postpartum (up to around Month 3 PP)

Secondary outcomes

  1. Change from baseline in the Mother-to-Infant Bonding Scale (MIBS) total score

    The MIBS is a simply designed short self-report measure for use from day one postpartum, offering one-word descriptors of possible emotions towards the baby to identify early difficulties in bonding (scale: 0-24, higher scores means worse outcome). This will be assessed in relation to recent childbirth.

    Time frame: Pre-Intervention and Post-Intervention (within 1 day of treatment)

  2. Change from baseline in the Mother-to-Infant Bonding Scale (MIBS) total score

    The MIBS is a simply designed short self-report measure for use from day one postpartum, offering one-word descriptors of possible emotions towards the baby to identify early difficulties in bonding (scale: 0-24, higher scores means worse outcome).This will be assessed in relation to recent childbirth.

    Time frame: Pre-Intervention and Month 2 postpartum (up to around Month 3 PP)

  3. Maternal Attachment Inventory (MAI) total score

    The MAI self-report asks about maternal feelings toward and perceptions of the infant; it is considered a robust tool to measure problems in mother-baby relationship (scale: 26-104, higher scores means better outcome). This will be assessed in relation to recent childbirth.

    Time frame: Post-intervention (within 1 day of treatment)

  4. Maternal Attachment Inventory (MAI) total score

    The MAI asks about maternal feelings toward and perceptions of the infant; it is considered a robust tool to measure problems in mother-baby relationship (scale: 26-104, higher scores means better outcome).This will be assessed in relation to recent childbirth.

    Time frame: Month 2 postpartum (up to around Month 3 PP)

  5. Change from baseline in the Edinburgh Postnatal Depression Scale (EPDS) total score

    The EPDS is a brief 10-item self-report measure (scale: 0-30, higher scores means worse outcome). It recommended for assessing for maternal depression in routine obstetrics care in the US.

    Time frame: Pre-Intervention and Post-Intervention (within 1 day of treatment)

  6. Change from baseline in the Edinburgh Postnatal Depression Scale (EPDS) total score

    The EPDS is a brief 10-item self-report measure (scale: 0-30, higher scores means worse outcome). It recommended for assessing for maternal depression in routine obstetrics care in the US.

    Time frame: Pre-Intervention and Month 2 postpartum (up to around Month 3 PP)

  7. Change from baseline in the posttraumatic growth inventory (PTG) total score

    The PTGI is a 21-item self-report measures that in used in research to assess positive change following a specific (potentially traumatic) event in regard to new possibilities, relating to others, personal strength, spiritual change, and appreciation of Life (scale: 0-125, higher scores means better outcome). This will be assessed in relation to recent childbirth.

    Time frame: Pre-Intervention and Post-Intervention (within 1 day of treatment)

  8. Change from baseline in the posttraumatic growth inventory (PTG) total score

    The PTGI is a 21-item self-report measures that in used in research to assess positive change following a specific (potentially traumatic) event in regard to new possibilities, relating to others, personal strength, spiritual change, and appreciation of Life (scale: 0-125, higher scores means better outcome). This will be assessed in relation to recent childbirth.

    Time frame: Pre-Intervention and Month 2 postpartum (up to around Month 3 PP)

  9. Behavioral mother-infant bonding as determined by a quantitative observational assessment of mother-infant interaction using the Coding Interactive Behavior (CIB)

    Mother-infant bonding behavior will be observed during a 5-min free-play session and coded using the well-validated CIB. The CIB is a global rating system that looks at affective states and interactive styles. Using video-recorded material, the CIB is broken down into 33 codes (18 parent, 8 child, and 7 dyad) rated on a 1-5 scale. Meaningful theory-based constructs, for example, maternal sensitivity (higher scores better outcome), will be used in final analysis

    Time frame: Month 2 postpartum (up to around Month 3 PP)

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02129, United States
08

References and documents

Publications

  • Yildiz PD, Ayers S, Phillips L. The prevalence of posttraumatic stress disorder in pregnancy and after birth: A systematic review and meta-analysis. J Affect Disord. 2017 Jan 15;208:634-645. doi: 10.1016/j.jad.2016.10.009. Epub 2016 Oct 27. PubMed 27865585 ↗
  • Pennebaker JW. Expressive Writing in Psychological Science. Perspect Psychol Sci. 2018 Mar;13(2):226-229. doi: 10.1177/1745691617707315. Epub 2017 Oct 9. PubMed 28992443 ↗
  • Pennebaker JW. Putting stress into words: health, linguistic, and therapeutic implications. Behav Res Ther. 1993 Jul;31(6):539-48. doi: 10.1016/0005-7967(93)90105-4. PubMed 8347112 ↗
  • Dekel S, Thiel F, Dishy G, Ashenfarb AL. Is childbirth-induced PTSD associated with low maternal attachment? Arch Womens Ment Health. 2019 Feb;22(1):119-122. doi: 10.1007/s00737-018-0853-y. Epub 2018 May 21. PubMed 29786116 ↗
  • Dekel S, Stuebe C, Dishy G. Childbirth Induced Posttraumatic Stress Syndrome: A Systematic Review of Prevalence and Risk Factors. Front Psychol. 2017 Apr 11;8:560. doi: 10.3389/fpsyg.2017.00560. eCollection 2017. PubMed 28443054 ↗
  • Chan SJ, Thiel F, Kaimal AJ, Pitman RK, Orr SP, Dekel S. Validation of childbirth-related posttraumatic stress disorder using psychophysiological assessment. Am J Obstet Gynecol. 2022 Oct;227(4):656-659. doi: 10.1016/j.ajog.2022.05.051. Epub 2022 May 29. PubMed 35640702 ↗
  • Dekel S, Ein-Dor T, Dishy GA, Mayopoulos PA. Beyond postpartum depression: posttraumatic stress-depressive response following childbirth. Arch Womens Ment Health. 2020 Aug;23(4):557-564. doi: 10.1007/s00737-019-01006-x. Epub 2019 Oct 25. PubMed 31650283 ↗
  • Berman Z, Thiel F, Dishy GA, Chan SJ, Dekel S. Maternal psychological growth following childbirth. Arch Womens Ment Health. 2021 Apr;24(2):313-320. doi: 10.1007/s00737-020-01053-9. Epub 2020 Jul 23. PubMed 32705348 ↗

Individual participant data

Plan to share: Yes

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05662423
Lead sponsor
Massachusetts General Hospital
Responsible party
Sharon Dekel, PhD (Assistant Professor in Psychology, Massachusetts General Hospital) — Principal investigator
First posted
Dec 22, 2022
Start date
Nov 8, 2023
Primary completion
Jul 29, 2026
Completion
Jul 29, 2026
Last update
Jul 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion